|
| Wednesday, September 27, 2017 |
|
|
Eisai: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA |
| This application is based on the results of the REFLECT study (Study 304), a multicenter, open-label, randomized, global Phase III trial comparing the efficacy and safety of Lenvima versus sorafenib, a standard treatment for HCC, as a first-line treatment for patients with unresectable HCC. more info >> |
|
| Friday, September 22, 2017 |
|
|
Eisai: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis |
| Eisai Co., Ltd. and Eisai's subsidiary for gastrointestinal disease area EA Pharma Co., Ltd. announced today that Eisai has obtained the approval of additional dosage and administration in Japan of the proton pump inhibitor Pariet 5 mg Tablets and 10 mg Tablets to administer 10 mg of rabeprazole sodium per dose twice-daily for the maintenance therapy of proton pump inhibitor-resistant reflux esophagitis. more info >> |
|
|
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC |
| Eisai Co., Ltd. announced today that the latest non-clinical data on MORAb-202, Eisai's first antibody-drug conjugate (ADC) developed by its research subsidiary Morphotek, Inc., was presented at the 8th Annual World ADC. more info >> |
|
| Tuesday, September 19, 2017 |
|
|
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference |
| In the total population analysis of this study, the treatment effect of lenvatinib for all patients on the primary endpoint of Overall Survival (OS) was demonstrated by statistical confirmation of non-inferiority to sorafenib. more info >> |
|
| Wednesday, September 13, 2017 |
|
|
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak |
| Eisai Co., Ltd. will launch Etak Antimicrobial Spray Alpha (classified as miscellaneous goods), which contains long-acting antimicrobial agent Etak, on September 19. more info >> |
|
| Tuesday, September 12, 2017 |
|
|
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out |
| Eisai Co., Ltd. and MAMORIO, Inc. have announced that the MeMAMORIO tracking tool to support people with dementia and seniors going out will be launched in Japan on September 13. more info >> |
|
|
Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017 |
| Eisai Co., Ltd. announced today that it has been selected for a fifth consecutive year of membership in the DJSI Asia Pacific, the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). more info >> |
|
|
Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress |
| Eisai Co., Ltd. has announced that new findings indicating its in-house discovered and developed anticancer agent lenvatinib mesylate delays deterioration in certain areas of health-related quality of life (QOL) in comparison to sorafenib were presented in an oral session at the ESMO 2017 Congress, which took place in Madrid, Spain. more info >> |
|
|
Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima (Lenvatinib) in Combination with Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress |
| Eisai Co., Ltd. announced today that an oral presentation on the results of the renal cell carcinoma cohort from a Phase Ib/II clinical study of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate. more info >> |
|
| Friday, September 8, 2017 |
|
|
Conclusion of Development Collaboration Agreement for Lenvima (Lenvatinib Mesylate) and Opdivo (Nivolumab) Combination Therapy for Treatment of Hepatocellular Carcinoma |
| Based on this agreement, Eisai and Ono will swiftly implement a Phase Ib clinical trial in Japan to investigate the safety, tolerability, and efficacy of the combination of Lenvima and Opdivo in patients with HCC. more info >> |
|
|
|
